SNDX SYNDAX PHARMACEUTICALS

Syndax Announces Participation in November Investor Conferences

Syndax Announces Participation in November Investor Conferences

NEW YORK, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that Michael A. Metzger, Chief Executive Officer, as well as members of the Syndax management team, will participate in the following upcoming investor conferences:

  • UBS Global Healthcare Conference 2025 with a fireside chat on Monday, November 10, 2025, at 11:00 a.m. ET.  
  • Guggenheim Second Annual Healthcare Innovation Conference with a fireside chat on Tuesday, November 11, 2025, at 3:00 p.m. ET.
  • Stifel 2025 Healthcare Conference with a fireside chat on Thursday, November 13, 2025, at 10:00 a.m. ET.
  • Jefferies 2025 London Healthcare Conference with a fireside chat on Thursday, November 20, 2025, at 10:00 a.m. GMT/ 5:00 a.m. ET.

A live webcast of the fireside chats will be available in the Investor section of the Company's website at , where a replay will also be available for a limited time.

About Syndax

Syndax Pharmaceuticals is a commercial-stage biopharmaceutical company advancing innovative cancer therapies. Highlights of the Company's pipeline include Revuforj® (revumenib), an FDA-approved menin inhibitor, and Niktimvo™ (axatilimab-csfr), an FDA-approved monoclonal antibody that blocks the colony stimulating factor 1 (CSF-1) receptor. Fueled by our commitment to reimagining cancer care, Syndax is working to unlock the full potential of its pipeline and is conducting several clinical trials across the continuum of treatment. For more information, please visit or follow the Company on and .

Syndax Contacts

Sharon Klahre

Syndax Pharmaceuticals, Inc.



Tel 781.684.9827

SNDX-G



EN
30/10/2025

Underlying

SNDXSYNDAX PHARMACEUTICALS

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on SYNDAX PHARMACEUTICALS

 PRESS RELEASE
Free
SNDX SYNDAX PHARMACE...

Syndax Announces Participation in November Investor Conferences

Syndax Announces Participation in November Investor Conferences NEW YORK, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that Michael A. Metzger, Chief Executive Officer, as well as members of the Syndax management team, will participate in the following upcoming investor conferences: UBS Global Healthcare Conference 2025 with a fireside chat on Monday, November 10, 2025, at 11:00 a.m. ET.  Guggenheim Second Annual Healthcare Innovation Conference with a fireside ...

20h / 56m 1 EN
 PRESS RELEASE
Free
SNDX SYNDAX PHARMACE...

Syndax to Announce Third Quarter 2025 Financial Results and Host Confe...

Syndax to Announce Third Quarter 2025 Financial Results and Host Conference Call and Webcast on November 3, 2025 NEW YORK, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that it will report its third quarter 2025 financial results and provide a business update on Monday, November 3, 2025. In connection with the earnings release, Syndax's management will host a conference call and live audio webcast at 4:30 p.m. ET on Monday, November 3, 2025. The live audio webca...

October 27, 2025 1 EN
 PRESS RELEASE
Free
SNDX SYNDAX PHARMACE...

Syndax Announces FDA Approval of Revuforj® (revumenib) in Adult and Pe...

Syndax Announces FDA Approval of Revuforj® (revumenib) in Adult and Pediatric Patients with Relapsed or Refractory NPM1 Mutated Acute Myeloid Leukemia – First and only therapy FDA approved in both R/R acute myeloid leukemia (AML) with an NPM1 mutation and R/R acute leukemia with a KMT2A translocation – – Second approved indication for Revuforj in less than one year further solidifies Syndax’s leadership in menin inhibition – – Included in NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for R/R NPM1 mutated AML – – Syndax to host conference call today at 2:30 p.m. ET – N...

October 24, 2025 1 EN
 PRESS RELEASE
Free
SNDX SYNDAX PHARMACE...

Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing ...

Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) NEW YORK, Oct. 03, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that on October 1, 2025 the Company granted inducement awards to purchase up to 138,900 shares of common stock to 10 new employees under the Company's 2023 Inducement Plan. The stock options will vest over four years, with 25% of the underlying shares vesting on the one-year anniversary of the vesting commencement date and 1...

October 3, 2025 1 EN
 PRESS RELEASE
Free
SNDX SYNDAX PHARMACE...

Syndax’s Revuforj® (revumenib) Included in NCCN Clinical Practice Guid...

Syndax’s Revuforj® (revumenib) Included in NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for the Treatment of Relapsed or Refractory NPM1 Mutated Acute Myeloid Leukemia NEW YORK, Sept. 19, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that the National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Acute Myeloid Leukemia were updated to include revumenib as a category 2A recommendation for relapsed o...

September 19, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch